DYAI
Price
$0.99
Change
+$0.02 (+2.06%)
Updated
Jun 6 closing price
Capitalization
29.19M
58 days until earnings call
VYNE
Price
$1.00
Change
-$0.00 (-0.00%)
Updated
Jun 6 closing price
Capitalization
16.66M
Interact to see
Advertisement

DYAI vs VYNE

Header iconDYAI vs VYNE Comparison
Open Charts DYAI vs VYNEBanner chart's image
Dyadic International
Price$0.99
Change+$0.02 (+2.06%)
Volume$33.23K
Capitalization29.19M
VYNE Therapeutics
Price$1.00
Change-$0.00 (-0.00%)
Volume$265.25K
Capitalization16.66M
DYAI vs VYNE Comparison Chart
Loading...
DYAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VYNE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DYAI vs. VYNE commentary
Jun 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DYAI is a StrongBuy and VYNE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 09, 2025
Stock price -- (DYAI: $1.00 vs. VYNE: $0.98)
Brand notoriety: DYAI and VYNE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DYAI: 33% vs. VYNE: 45%
Market capitalization -- DYAI: $29.19M vs. VYNE: $16.66M
DYAI [@Biotechnology] is valued at $29.19M. VYNE’s [@Biotechnology] market capitalization is $16.66M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DYAI’s FA Score shows that 0 FA rating(s) are green whileVYNE’s FA Score has 1 green FA rating(s).

  • DYAI’s FA Score: 0 green, 5 red.
  • VYNE’s FA Score: 1 green, 4 red.
According to our system of comparison, VYNE is a better buy in the long-term than DYAI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DYAI’s TA Score shows that 4 TA indicator(s) are bullish while VYNE’s TA Score has 4 bullish TA indicator(s).

  • DYAI’s TA Score: 4 bullish, 4 bearish.
  • VYNE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both DYAI and VYNE are a good buy in the short-term.

Price Growth

DYAI (@Biotechnology) experienced а -2.43% price change this week, while VYNE (@Biotechnology) price change was -2.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +10.01%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

DYAI is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DYAI($29.2M) has a higher market cap than VYNE($16.7M). DYAI YTD gains are higher at: -42.571 vs. VYNE (-70.896). DYAI has higher annual earnings (EBITDA): -7.42M vs. VYNE (-43.63M). VYNE has more cash in the bank: 61.5M vs. DYAI (9.92M). VYNE has less debt than DYAI: VYNE (99K) vs DYAI (5.37M). DYAI has higher revenues than VYNE: DYAI (3.37M) vs VYNE (501K).
DYAIVYNEDYAI / VYNE
Capitalization29.2M16.7M175%
EBITDA-7.42M-43.63M17%
Gain YTD-42.571-70.89660%
P/E RatioN/A0.71-
Revenue3.37M501K672%
Total Cash9.92M61.5M16%
Total Debt5.37M99K5,424%
FUNDAMENTALS RATINGS
DYAI vs VYNE: Fundamental Ratings
DYAI
VYNE
OUTLOOK RATING
1..100
5160
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
34
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
9296
P/E GROWTH RATING
1..100
691
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VYNE's Valuation (34) in the Pharmaceuticals Major industry is somewhat better than the same rating for DYAI (94) in the Biotechnology industry. This means that VYNE’s stock grew somewhat faster than DYAI’s over the last 12 months.

VYNE's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as DYAI (100) in the Biotechnology industry. This means that VYNE’s stock grew similarly to DYAI’s over the last 12 months.

VYNE's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as DYAI (98) in the Biotechnology industry. This means that VYNE’s stock grew similarly to DYAI’s over the last 12 months.

DYAI's Price Growth Rating (92) in the Biotechnology industry is in the same range as VYNE (96) in the Pharmaceuticals Major industry. This means that DYAI’s stock grew similarly to VYNE’s over the last 12 months.

VYNE's P/E Growth Rating (1) in the Pharmaceuticals Major industry is significantly better than the same rating for DYAI (69) in the Biotechnology industry. This means that VYNE’s stock grew significantly faster than DYAI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DYAIVYNE
RSI
ODDS (%)
Bullish Trend 12 days ago
71%
Bullish Trend 12 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 12 days ago
87%
Bullish Trend 12 days ago
78%
Momentum
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 12 days ago
88%
MACD
ODDS (%)
Bearish Trend 12 days ago
87%
Bearish Trend 12 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 12 days ago
88%
Bearish Trend 12 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 12 days ago
89%
Bearish Trend 12 days ago
88%
Advances
ODDS (%)
Bullish Trend 21 days ago
81%
Bullish Trend about 1 month ago
79%
Declines
ODDS (%)
Bearish Trend 13 days ago
87%
Bearish Trend 12 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 12 days ago
82%
Bullish Trend 12 days ago
77%
Aroon
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 12 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
DYAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VYNE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

DYAI and

Correlation & Price change

A.I.dvisor tells us that DYAI and FBRX have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DYAI and FBRX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DYAI
1D Price
Change %
DYAI100%
+6.91%
FBRX - DYAI
29%
Poorly correlated
-16.13%
CGTX - DYAI
28%
Poorly correlated
-5.76%
APLS - DYAI
26%
Poorly correlated
-0.53%
VYNE - DYAI
24%
Poorly correlated
-2.50%
AVIR - DYAI
23%
Poorly correlated
-0.51%
More

VYNE and

Correlation & Price change

A.I.dvisor indicates that over the last year, VYNE has been loosely correlated with IRON. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if VYNE jumps, then IRON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VYNE
1D Price
Change %
VYNE100%
-2.50%
IRON - VYNE
37%
Loosely correlated
-1.66%
EYPT - VYNE
35%
Loosely correlated
+18.12%
ELVN - VYNE
33%
Loosely correlated
+0.50%
TRDA - VYNE
33%
Poorly correlated
+0.91%
TPST - VYNE
32%
Poorly correlated
+1.94%
More